Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its second super short-term financing bond for 2025, with a total issuance amount of 50 million yuan [1] - The bond, named "25 Nanjing Pharmaceutical SCP002," has an interest rate of 1.94% and a maturity period of 179 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be 50,475.70 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the interbank market clearing house before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the clearing house of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

证券代码：600713 证券简称：南京医药 编号：ls2025-109 2025 年 6 月 23-25 日，公司第十届董事会临时会议审议通过《关于公司公开 挂牌出租南京市秦淮区延龄巷 27 号房地产的议案》。董事会同意公司公开挂牌 出租标的资产，挂牌出租起始年租金租赁价格为 711.55 万元/年（人民币，下同）。 出租总面积 13,325.11 平方米（以实际可租赁面积为准），租赁期限为 13 年（156 个月，免租期为 6 个月，租赁期前三年均摊）。租金按季支付，租金单价前三年 不变，第四年起开始递增，每三年在上一年租金的基础上递增 5%，租赁期的租 金总收入预计为 9,709.73 万元。最终成交价格及承租人根据公开挂牌结果予以确 定。董事会同时授权公司经营层具体办理上述资产挂牌出租相关事宜。详情请见 公司于 2025 年 6 月 26 日对外披露的编号为 ls2025-093 之《南京医药股份有限公 司关于公开挂牌出租南京市秦淮区延龄巷 27 号房地产的公告》。 二、挂牌进展情况 2025 年 7 月 16 日至 2025 年 7 月 29 日，标的资产在南京市公共资源交易中 心挂牌，公开征集承租人 ...

Core Points - Nanjing Pharmaceutical Co., Ltd. announced the progress of leasing a property located at 27 Yanling Lane, Qinhuai District, Nanjing [1] - The board of directors approved the public listing for lease from June 23 to June 25, 2025, with an initial annual rent of 7.1155 million yuan and a lease term of 13 years, expecting total rental income of 97.0973 million yuan [1] - The solicitation for tenants took place from July 16 to July 29, with only Wangu Enterprise Management Group Co., Ltd. meeting the qualification criteria [1] - On August 20, the company received a confirmation of transaction, with Wangu Company as the lessee at the agreed price of 7.1155 million yuan per year, totaling 97.0973 million yuan [1] - Wangu Company has a registered capital of 66.6667 million yuan and is not related to Nanjing Pharmaceutical [1]

Core Points - Nanjing Pharmaceutical announced the use of 170 million yuan of temporarily idle raised funds to purchase a large corporate time deposit from Minsheng Bank, which matured on August 19, 2025 [2] - The company redeemed the principal of 170 million yuan and earned investment income of 573,800 yuan, which met expectations [2] - The company plans to continue using the same amount of 170 million yuan to purchase another large time deposit from Minsheng Bank with a term of 3 months and an annualized yield of 1.10% [2]

Core Viewpoint - The pharmaceutical distribution industry is characterized by three main business models: wholesale, retail, and various new distribution models, each with distinct operational dynamics and market implications [1]. Group 1: Wholesale Model - The wholesale model, also known as the distribution model, involves selling pharmaceuticals and medical devices in bulk to entities that directly interact with consumers, such as medical institutions and retail pharmacies [4]. - The third terminal in the wholesale model is increasingly favored by internet hospitals, indicating a shift towards digital integration in pharmaceutical distribution [4]. Group 2: Retail Model - The retail model involves retail pharmacies purchasing pharmaceutical products from manufacturers or other distributors and selling them to individual consumers, generating profit from the price difference [7]. - Although the retail model operates on a smaller scale compared to wholesale, it boasts higher profit margins, making it an attractive segment within the pharmaceutical distribution landscape [7]. Group 3: Internet Retail Model - The internet retail model encompasses various online platforms, including internet hospitals and pharmaceutical e-commerce, facilitating diagnosis and drug sales through digital channels [9]. - This model includes B2B, B2C, and O2O formats, reflecting the growing trend of digital transformation in the pharmaceutical sector [9]. Group 4: Third-Party Cold Chain Logistics - The "14th Five-Year Plan" emphasizes the need for a modern, intelligent pharmaceutical supply chain, focusing on enhancing networked, scaled, and specialized logistics services [12]. - Third-party cold chain logistics offer significant advantages, such as reducing initial investment costs for pharmaceutical companies and ensuring temperature-controlled transport, which is crucial for maintaining drug quality [12]. - These logistics providers can effectively manage reverse logistics and product recalls through advanced tracking and data exchange systems, thereby minimizing losses and ensuring compliance with quality standards [12].

Core Viewpoint - The pharmaceutical distribution industry is categorized into three main business models: wholesale, retail, and various new distribution models, each with distinct characteristics and profit margins [1]. Group 1: Wholesale Model - The wholesale model, also known as the distribution model, involves selling pharmaceuticals and medical devices in bulk to entities that directly interact with consumers, such as medical institutions and retail pharmacies [3]. - The wholesale model can be further divided into categories such as hospital direct sales, commercial allocation, and third terminal distribution, with the third terminal being a key focus for internet healthcare companies [3]. Group 2: Retail Model - The retail model involves retail pharmacies purchasing pharmaceutical products from manufacturers or other distribution companies and selling them to individual consumers for profit [4]. - Although the retail model is smaller in scale compared to wholesale, it offers higher profit margins, and can be subdivided into single-store and chain models, with chain models further categorized into direct-operated and franchise operations [4]. Group 3: Internet Retail Model - The internet pharmaceutical new retail model encompasses various internet hospitals and pharmaceutical e-commerce platforms that conduct diagnosis and drug sales through online channels, including B2B, B2C, and O2O models [6]. Group 4: Third-Party Cold Chain Logistics - The pharmaceutical distribution industry is expected to build a modern smart pharmaceutical supply chain service system during the 14th Five-Year Plan period, focusing on enhancing networked, scaled, and specialized levels for safer and more efficient logistics [10]. - Third-party cold chain logistics provide significant advantages, such as reducing upfront investment for pharmaceutical companies, ensuring temperature control during transport, and optimizing the pharmaceutical supply chain through integrated information management [11].

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

证券代码：600713 证券简称：南京医药 编号：ls2025-108 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2025 年度第二期超短期融资券兑付公告 为保证南京医药股份有限公司 2025 年度第二期超短期融资券（债券简称：25 南京医药 SCP002，债券代码：012580666）兑付工作的顺利进行，现将有关事宜 公告如下： （一）发行人：南京医药股份有限公司 联系人：周昊鹏 联系方式：025-84552638 （二）存续期管理机构：杭州银行股份有限公司 联系人：王心悦 联系方式：0571-86475508 （三）登记托管机构：银行间市场清算所股份有限公司 联系部门：运营部 联系人：谢晨燕、陈龚荣 联系方式：021-23198708、021-23198682 | 发行人名称 | 南京医药股份有限公司 | | | --- | --- | --- | | 债项名称 | 南京医药股份有限公司 2025 | 年度第二期 | | | 超短期融资券 | | | 债项简称 | 南京医药 25 | SCP002 | | 债项代码 | 012580666 | | | 发行金额（万元） | 50,0 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-107 债券代码：110098 债券简称：南药转债 2024 年度第三期超短期融资券兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2024 年度第三期超短期融资券（债券简称：24 南京医药 SCP003，债券代码：012483960）兑付工作的顺利进行，现将有关事宜 公告如下： | 发行人名称 | 南京医药股份有限公司 | | --- | --- | | 债项名称 | 南京医药股份有限公司 2024 年度第三期超 | | | 短期融资券 | | 债项简称 | 24 南京医药 SCP003 | | 债项代码 | 012483960 | | 发行金额（万元） | 50,000 | | 起息日 | 2024-12-17 | | 发行期限 | 269 天 | | 债项余额（万元） | 50,000 | | 最新评级情况 | / | | 偿还类别 | 本息兑付 | | 本计息期债项利率 | 1.8% | | 本息兑付日 | 2025- ...